Cite

    Shiomi, M. et al. (2019). Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon‐like peptide‐1 receptor agonists. Journal of diabetes investigation. 10 (2), pp. 408-417. [Online].